These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 1376935)
1. Serum prostate-specific antigen in monitoring the response of carcinoma of the prostate to radiation therapy. Fijuth J; Chauvet B; Vincent P; Félix-Faure C; Reboul F Radiother Oncol; 1992 Apr; 23(4):236-40. PubMed ID: 1376935 [TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Zagars GK Int J Radiat Oncol Biol Phys; 1992; 23(1):47-53. PubMed ID: 1374065 [TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy. Chauvet B; Félix-Faure C; Lupsascka N; Fijuth J; Brewer Y; Davin JL; Kirscher S; Reboul F J Clin Oncol; 1994 Jul; 12(7):1402-7. PubMed ID: 7517443 [TBL] [Abstract][Full Text] [Related]
4. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. Zagars GK J Urol; 1994 Nov; 152(5 Pt 2):1786-91. PubMed ID: 7523725 [TBL] [Abstract][Full Text] [Related]
5. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Kollmeier MA; Stock RG; Stone N Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768 [TBL] [Abstract][Full Text] [Related]
6. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. Zietman AL; Coen JJ; Shipley WU; Willett CG; Efird JT J Urol; 1994 Mar; 151(3):640-5. PubMed ID: 7508522 [TBL] [Abstract][Full Text] [Related]
7. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome. Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766 [TBL] [Abstract][Full Text] [Related]
8. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome. Zagars GK; Pollack A Urology; 1995 Mar; 45(3):476-83. PubMed ID: 7533459 [TBL] [Abstract][Full Text] [Related]
9. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961 [TBL] [Abstract][Full Text] [Related]
10. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy. Miller N; Smolkin ME; Bissonette E; Theodorescu D Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361 [TBL] [Abstract][Full Text] [Related]
11. Outcome and predictive factors for patients with Gleason score 7 prostate carcinoma treated with three-dimensional conformal external beam radiation therapy. Anderson PR; Hanlon AL; Horwitz E; Pinover W; Hanks GE Cancer; 2000 Dec; 89(12):2565-9. PubMed ID: 11135217 [TBL] [Abstract][Full Text] [Related]
12. Prostate specific antigen levels during and after external beam radiotherapy for localized carcinoma of the prostate: predictor of therapeutic efficacy. Rodrigus P; van Landeghem AA Strahlenther Onkol; 1992 Jul; 168(7):397-401. PubMed ID: 1379747 [TBL] [Abstract][Full Text] [Related]
14. Hazards of dose escalation in prostate cancer radiotherapy. Kuban D; Pollack A; Huang E; Levy L; Dong L; Starkschall G; Rosen I Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1260-8. PubMed ID: 14630260 [TBL] [Abstract][Full Text] [Related]
15. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. Lee WR; Hanlon AL; Hanks GE J Urol; 1996 Aug; 156(2 Pt 1):450-3. PubMed ID: 8683700 [TBL] [Abstract][Full Text] [Related]
16. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate. Zagars GK; Pollack A; Smith LG Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):809-19. PubMed ID: 10386637 [TBL] [Abstract][Full Text] [Related]